|Bid||231.00 x 800|
|Ask||236.00 x 800|
|Day's Range||230.96 - 235.42|
|52 Week Range||198.64 - 258.45|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||19.37|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||7.76 (3.14%)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||251.76|
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Amgen (AMGN) closed at $233.02 in the latest trading session, marking a +1.12% move from the prior day.
On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.